{
    "id": 1002,
    "fullName": "MET amp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "MET amp indicates an increased number of copies of the MET gene. However, the mechanism causing the increase is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4233,
        "geneSymbol": "MET",
        "terms": [
            "MET",
            "AUTS9",
            "c-Met",
            "DFNB97",
            "HGFR",
            "RCCP2"
        ]
    },
    "variant": "amp",
    "createDate": "07/16/2014",
    "updateDate": "04/25/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10067,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Altiratinib (DCC-0701) inhibited Met phosphorylation and proliferation of a gastric cancer cell line with MET amplification and over expression in culture, and inhibited tumor growth and induced tumor regression in xenograft models (PMID: 26285778).",
            "molecularProfile": {
                "id": 1066,
                "profileName": "MET amp MET over exp"
            },
            "therapy": {
                "id": 1656,
                "therapyName": "Altiratinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7263,
                    "pubMedId": 26285778,
                    "title": "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26285778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 799,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In preclinical studies, a MET amplified, gastric carcinoma cell over expressing Met was sensitive to K252a treatment in both culture and mouse model experiments (PMID: 12118367).",
            "molecularProfile": {
                "id": 1066,
                "profileName": "MET amp MET over exp"
            },
            "therapy": {
                "id": 1088,
                "therapyName": "K252a",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 451,
                    "pubMedId": 12118367,
                    "title": "K252a inhibits the oncogenic properties of Met, the HGF receptor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12118367"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21102,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment inhibited MET phosphorylation and induced tumor regression in patient-derived xenograft (PDX) models of lung adenocarcinoma with MET overexpression and MET amplification, including one model with a copy number gain of 11 and another model with a copy number gain of 14 (PMID: 30674502).",
            "molecularProfile": {
                "id": 1066,
                "profileName": "MET amp MET over exp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18032,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in gradual reduction of tumor size in a patient with lung adenocarcinoma harboring low-level MET amplification and high Met expression by IHC (3+), until disease progression at 20.7 months (PMID: 31200822).",
            "molecularProfile": {
                "id": 1066,
                "profileName": "MET amp MET over exp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15967,
                    "pubMedId": 31200822,
                    "title": "Acquired KRAS mutation and loss of low-level MET amplification after durable response to crizotinib in a patient with lung adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31200822"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10063,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Altiratinib (DCC-2701) inhibited Met phosphorylation and proliferation of a non-small cell lung cancer cell line with MET amplification and overexpression in culture (PMID: 26285778).",
            "molecularProfile": {
                "id": 1066,
                "profileName": "MET amp MET over exp"
            },
            "therapy": {
                "id": 1656,
                "therapyName": "Altiratinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7263,
                    "pubMedId": 26285778,
                    "title": "Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26285778"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9967,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sym015 inhibited growth of cancer cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified patient-derived xenograft (PDX) models (Cancer Res July 15 2016 (76) (14 Supplement) 1219).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 4322,
                "therapyName": "SYM015",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7828,
                    "pubMedId": null,
                    "title": "Abstract 1219: Sym015, a novel antibody mixture targeting non-overlapping epitopes of MET, effectively inhibits growth of MET dependent tumors and overcomes resistance to a single monoclonal antibody",
                    "url": "http://cancerres.aacrjournals.org/content/76/14_Supplement/1219"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16869,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in a completed response that sustained for 22 weeks in a patient with triple-receptor negative breast cancer harboring a 30-fold amplification of MET, with MET overexpression and hyperactivity confirmed by IHC (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1317).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14988,
                    "pubMedId": null,
                    "title": "Exceptional responses to crizotinib in breast cancer patients with somatic MET and ROS1 alterations.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7727,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of gastric carcinoma harboring MET amplification (PMID: 23553846).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 726,
                "therapyName": "EMD 1214063",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 336,
                    "pubMedId": 23553846,
                    "title": "EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23553846"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8712,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited proliferation of a MET-amplified non-small cell lung cancer cell line in culture (PMID: 27550450).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 4799,
                "therapyName": "KTN0073-IgG2",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6713,
                    "pubMedId": 27550450,
                    "title": "Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550450"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10756,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of gastric cancer cell lines in culture and in cell line xenograft models (PMID: 19832844).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1019,
                "therapyName": "Golvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 41,
                    "pubMedId": 19832844,
                    "title": "E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19832844"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17502,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MTI-31 inhibited proliferation a non-small cell lung cancer cell line with MET amplification in culture, and inhibited tumor growth in xenograft models (PMID: 30796032).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 8516,
                "therapyName": "MTI-31",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15515,
                    "pubMedId": 30796032,
                    "title": "A Novel mTORC1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial-Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30796032"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11344,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, MET amplification was associated with resistance to Erbitux (cetuximab) in 2 colorectal cancer patients, and in patient-derived xenograft (PDX) models (PMID: 23729478).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 694,
                "therapyName": "Cetuximab",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9245,
                    "pubMedId": 23729478,
                    "title": "Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11345,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JNJ-38877605 inhibited tumor growth in colorectal cancer patient-derived xenograft models with MET amplification (PMID: 23729478).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 783,
                "therapyName": "JNJ 38877605",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9245,
                    "pubMedId": 23729478,
                    "title": "Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23729478"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21094,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) combined with Taxotere (docetaxel) synergistically induced killing of lung cancer cell lines harboring a MET amplification in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 9547,
                "therapyName": "Capmatinib + Docetaxel",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9172,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SGX523 inhibited survival of MET-amplified non-small cell lung cancer cells in culture (PMID: 26483207).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 916,
                "therapyName": "SGX523",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6982,
                    "pubMedId": 26483207,
                    "title": "c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26483207"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3936,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAE226 treatment inhibited proliferation of non-small cell lung carcinoma cell lines harboring MET amplification in culture (PMID: 26090892).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 2086,
                "therapyName": "TAE226",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4301,
                    "pubMedId": 26090892,
                    "title": "TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26090892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5558,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, treatment with Met inhibitors, including AMG 337 or EMD 1204831, resulted in stable disease in 29% (2/7) of advanced solid tumor patients harboring MET amplification while 10% (14/134) of MET non-amplified patients achieved partial response (PMID: 25326232).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 725,
                "therapyName": "EMD 1204831",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5104,
                    "pubMedId": 25326232,
                    "title": "Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25326232"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16840,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TPX-0022 treatment resulted in tumor regression in patient-derived xenograft (PDX) models of hepatocellular carcinoma harboring MET amplification (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1321).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 8205,
                "therapyName": "TPX-0022",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14951,
                    "pubMedId": null,
                    "title": "TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC for treatment of cancers with abnormal HGF/MET signaling.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21105,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Cometriq (cabozantinib) treatment inhibited proliferation of a lung cancer cell line harboring a MET amplification in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9027,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 337 inhibited growth of gastric cancer cell lines in culture, and inhibited growth and induced regression of tumors in MET-amplified gastric cancer cell line xenograft models (PMID: 27196782).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6878,
                    "pubMedId": 27196782,
                    "title": "In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196782"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5898,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MET amplified gastric cancer cell lines were sensitive to TAS-115, resulting in suppression of cell proliferation in culture (PMID: 24140932).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 3976,
                "therapyName": "TAS-115",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5188,
                    "pubMedId": 24140932,
                    "title": "The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24140932"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9176,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, disruption of multiple kinases with Hsp90 inhibitor Alvespimycin inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture and in cell line xenograft models (PMID: 26483207).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 627,
                "therapyName": "Alvespimycin",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6982,
                    "pubMedId": 26483207,
                    "title": "c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26483207"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9175,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, disruption of multiple kinases with Hsp90 inhibitor Ganetespib inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 745,
                "therapyName": "Ganetespib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6982,
                    "pubMedId": 26483207,
                    "title": "c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26483207"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12325,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glesatinib (MGCD265) inhibited Met phosphorylation and growth of MET-amplified lung cancer cells in culture (PMID: 28765324).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5555,
            "approvalStatus": "Clinical Study",
            "evidenceType": "Emerging",
            "efficacyEvidence": "In a retrospective study, advanced solid tumor patients harboring MET amplification demonstrated worse overall survival (7.23 months) comparing to patients without MET amplification (8.62 months) (PMID: 25326232), suggesting that this may serve as a future prognostic biomarker.",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5104,
                    "pubMedId": 25326232,
                    "title": "Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25326232"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13579,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCC244 inhibited Met activity, downstream signaling, and cell proliferation in lung squamous cell carcinoma cells harboring MET amplification in culture, and inhibited tumor growth in cell line xenograft models (PMID: 29237805).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 6844,
                "therapyName": "SCC244",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11200,
                    "pubMedId": 29237805,
                    "title": "Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29237805"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7728,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, EMD 1214063 induced tumor regression in mouse cell line xenograft models of non-small cell lung carcinoma harboring MET amplification (PMID: 23553846).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 726,
                "therapyName": "EMD 1214063",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 336,
                    "pubMedId": 23553846,
                    "title": "EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23553846"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21093,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment combined with Tarceva (erlotinib) enhanced killing of a lung cancer cell line harboring a MET amplification in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 8282,
                "therapyName": "Capmatinib + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21096,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, addition of Venclexta (venetoclax) to Capmatinib (INC280) did not demonstrate synergistic killing in lung cancer cell lines harboring a MET amplification compared to Capmatinib (INC280) in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 9548,
                "therapyName": "Capmatinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 988,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) in combination with BEZ235, synergistically inhibited proliferation of an Iressa (gefitinib)-resistant NSCLC cell line harboring MET amplification in culture and in cell line xenograft models (PMID: 24939055).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1420,
                "therapyName": "BEZ235 + Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 642,
                    "pubMedId": 24939055,
                    "title": "Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24939055"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3178,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, Tepotinib (MSC2156119J) demonstrated safety and preliminary efficacy in advanced solid tumor patients with MET amplification (JCO, Vol 33, No 15_suppl (May 20 Supplement), 2015: 2591).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1398,
                "therapyName": "Tepotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3666,
                    "pubMedId": null,
                    "title": "Efficacy, safety, biomarkers, and phase II dose modeling in a phase I trial of the oral selective c-Met inhibitor tepotinib (MSC2156119J).",
                    "url": "http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/2591"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21098,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) combined with A-1155463 synergistically induced killing of a lung cancer cell line harboring a MET amplification in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 9550,
                "therapyName": "A-1155463 + Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21111,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment inhibited phosphorylation of Met, Akt and Erk, and reduced proliferation and viability of lung cancer cell lines harboring a MET amplification in culture, and induced enhanced tumor regression in a cell line xenograft model (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9173,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the multitarget kinase inhibitor Sprycel (dasatinib) inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6982,
                    "pubMedId": 26483207,
                    "title": "c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26483207"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7731,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR125844 inhibited Met signaling, leading to growth inhibition of MET amplified lung cancer cells in culture (PMID: 25504634).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 2159,
                "therapyName": "SAR125844",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2009,
                    "pubMedId": 25504634,
                    "title": "The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25504634"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9970,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a gastric cancer patient harboring MET amplification was sensitive to treatment with ARGX-111, demonstrating stable disease, a metabolic response, and a decrease in circulating tumor cells (Journal of Clinical Oncology 33, no. 15_suppl (May 2015) 2580-2580).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 2157,
                "therapyName": "ARGX-111",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7830,
                    "pubMedId": null,
                    "title": "A phase I, first-in-human study of argx-111, a monoclonal antibody targeting c-met in patients with solid tumors",
                    "url": "http://ascopubs.org/doi/abs/10.1200/jco.2015.33.15_suppl.2580"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 981,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with MET amplification (PMID: 24939055).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 642,
                    "pubMedId": 24939055,
                    "title": "Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24939055"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16763,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AMG 337 treatment resulted in an objective response rate (ORR) of 29.6% (8/27) and a median duration of response (mDOR) of 197 days in patients with MET amplified advanced solid tumors, compared to an ORR of 9.9% (11/111) and mDOR of 202 days in all patients (PMID: 30425090; NCT01253707).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 14840,
                    "pubMedId": 30425090,
                    "title": "Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30425090"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5557,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, treatment with Met inhibitors, including AMG 337 or EMD 1204831, resulted in stable disease in 29% (2/7) of advanced solid tumor patients harboring MET amplification while 10% (14/134) of MET non-amplified patients achieved partial response (PMID: 25326232).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "conflicting",
            "references": [
                {
                    "id": 5104,
                    "pubMedId": 25326232,
                    "title": "Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25326232"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 21100,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment inhibited tumor growth in a cell line xenograft model of liver cancer harboring a MET amplification (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18781,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OMO-1 inhibited tumor growth in a cell line xenograft model of MET-amplified gastric cancer (Cancer Res 2018;78(13 Suppl):Abstract nr 4791).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 8846,
                "therapyName": "OMO-1",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16455,
                    "pubMedId": null,
                    "title": "OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models",
                    "url": "https://cancerres.aacrjournals.org/content/78/13_Supplement/4791"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16766,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AMG 337 treatment resulted in a partial response in a patient with MET amplified non-small cell lung cancer (PMID: 30425090; NCT01253707).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 14840,
                    "pubMedId": 30425090,
                    "title": "Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30425090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17158,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, AMG 337 treatment resulted in no objective response (0/3) and only stable disease in 33% (1/3) of patients with MET-amplified non-small cell lung cancer (PMID: 30366938; NCT02016534).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 15223,
                    "pubMedId": 30366938,
                    "title": "A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30366938"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9979,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, ABBV-399 inhibited growth of MET-amplified gastric cancer cell in culture, and induced tumor regression in a MET-amplified gastric cancer cell line xenograft model (PMID: 27573171).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1363,
                "therapyName": "Telisotuzumab vedotin",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7833,
                    "pubMedId": 27573171,
                    "title": "ABBV-399, a c-Met Antibody-Drug Conjugate that Targets Both MET-Amplified and c-Met-Overexpressing Tumors, Irrespective of MET Pathway Dependence.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27573171"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9028,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 337 inhibited growth of MET-amplified lung cancer cell lines in culture (PMID: 27196782).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6878,
                    "pubMedId": 27196782,
                    "title": "In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196782"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16838,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TPX-0022 inhibits phosphorylation of Met and downstream signaling, resulted in growth inhibition of MET amplified gastric cancer cell lines in culture and in cell line xenograft models (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1321).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 8205,
                "therapyName": "TPX-0022",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14951,
                    "pubMedId": null,
                    "title": "TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC for treatment of cancers with abnormal HGF/MET signaling.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3937,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TAE226 treatment inhibited proliferation of gastric cancer cell lines harboring MET amplification in culture (PMID: 26090892).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 2086,
                "therapyName": "TAE226",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4301,
                    "pubMedId": 26090892,
                    "title": "TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26090892"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11441,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, treatment with Savolitinib (AZD6094) resulted in an overall response rate (ORR) of 18% (8/44, all partial responses) in the subgroup of patients with MET-driven papillary renal cell carcinoma (PRCC), which included patients with MET amplification, compared to an ORR of 0% (0/46) in patients with MET-independent PRCC (PMID: 28644771; NCT02127710).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 2161,
                "therapyName": "Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4465,
                "name": "papillary renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9389,
                    "pubMedId": 28644771,
                    "title": "Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28644771"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 2460,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Savolitinib (AZD6094) demonstrated antitumor activity in patient-derived papillary renal cell carcinoma xenograft models harboring MET amplification (PMID: 25779944).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 2161,
                "therapyName": "Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4465,
                "name": "papillary renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3106,
                    "pubMedId": 25779944,
                    "title": "The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25779944"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17588,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, treatment with Savolitinib (AZD6094) was well-tolerated and resulted in partial response in 8% (3/39) of patients with advanced solid tumors, with all 3 responses in patients with papillary renal cell carcinoma, 1 with MET amplification and 2 with chromosome 7 gain (PMID: 30952639; NCT01773018).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 2161,
                "therapyName": "Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 4465,
                "name": "papillary renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15687,
                    "pubMedId": 30952639,
                    "title": "First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Antitumor Activity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30952639"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9171,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SGX523 inhibited Met signaling and proliferation of MET amplified gastric cancer cells in culture, resulted in tumor growth inhibition in cell line xenograft models (PMID: 19934279).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 916,
                "therapyName": "SGX523",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6981,
                    "pubMedId": 19934279,
                    "title": "SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19934279"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6929,
            "approvalStatus": "Preclinical - Pdx & cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AMG 337 inhibited Met phosphorylation and growth of hepatocellular carcinoma (HCC) cell lines with MET amplification in culture, and inhibited tumor growth in MET-amplified HCC patient-derived xenograft models (PMID: 27196749).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5957,
                    "pubMedId": 27196749,
                    "title": "Preclinical Evaluation of AMG 337, a Highly Selective Small Molecule MET Inhibitor, in Hepatocellular Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196749"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7604,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, M-COPA reduced Met cell surface expression and downstream signaling and decreased growth of MET-amplified gastric cancer cell lines in culture, and demonstrated antitumor activity in MET-amplified gastric cancer cell line xenograft models (PMID: 27197184).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 4522,
                "therapyName": "M-COPA",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6440,
                    "pubMedId": 27197184,
                    "title": "M-COPA, a Golgi Disruptor, Inhibits Cell Surface Expression of MET Protein and Exhibits Antitumor Activity against MET-Addicted Gastric Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27197184"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7066,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Capmatinib (INC280) treatment resulted in partial response in 63% (5/8) of MET amplified non-small cell lung carcinoma patients (J Clin Oncol 34, 2016 (suppl; abstr 9067)).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6064,
                    "pubMedId": null,
                    "title": "Phase (Ph) I study of the safety and efficacy of the cMET inhibitor capmatinib (INC280) in patients (pts) with advanced cMET+ non-small cell lung cancer (NSCLC).",
                    "url": "http://meetinglibrary.asco.org/content/165406-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8495,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Debio 1347 did not inhibit tumor growth in cell line xenograft models of MET amplified gastric cancer (PMID: 26438159).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1014,
                "therapyName": "Debio 1347",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12330,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glesatinib (MGCD265) treatment resulted in tumor regression in MET-amplified gastric cancer cell line xenograft models (PMID: 28765324).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21104,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tepotinib (MSC2156119J) treatment inhibited proliferation of a lung cancer cell line harboring a MET amplification in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1398,
                "therapyName": "Tepotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1634,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, INC280 displayed safety and preliminary efficacy in patients with MET dependent solid tumors (J Clin Oncol 32:5s, 2014 (suppl; abstr 2520)).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4034,
                    "pubMedId": null,
                    "title": "Phase I study of the safety and efficacy of INC280 in patients with advanced MET-dependent solid tumors.",
                    "url": "http://meetinglibrary.asco.org/content/128427-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1773,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR125844 inhibited Met signaling leading to growth inhibition of MET amplified gastric cancer cell lines in culture and in xenograft models (PMID: 25504634).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 2159,
                "therapyName": "SAR125844",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2009,
                    "pubMedId": 25504634,
                    "title": "The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25504634"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12970,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Xalkori (crizotinib) is included in guidelines for non-small cell lung cancer patients with high level MET amplification (NCCN.org).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19724,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (METROS), Xalkori (crizotinib) treatment resulted in a response rate of 31.3% (5/16), with a duration of response of 3.7 months, a median progression-free survival of 5.0 months, and a median overall survival of 5.3 months in patients with pre-treated non-small cell lung cancer harboring MET amplification (PMID: 31416808; NCT02499614).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17527,
                    "pubMedId": 31416808,
                    "title": "Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31416808"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17871,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a non-small cell lung cancer patient with MET amplification demonstrated a partial response to first-line treatment with Xalkori (crizotinib) with improvement in performance status (PMID: 31156053).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 15843,
                    "pubMedId": 31156053,
                    "title": "An advanced c-MET-amplified NSCLC patient that was treated with crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31156053"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9178,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited tumor grow in patient-derived xenograft models of MET amplified non-small cell lung cancer (PMID: 26483207).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6982,
                    "pubMedId": 26483207,
                    "title": "c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26483207"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4080,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AMG 337 treatment resulted in complete response in 10% (1/10), partial response in 40% (4/10), and stable disease in 20% (2/10) of patients with MET amplified gastroesophageal cancer (J Clin Oncol 33, no. 3_suppl (January 20 2015) 1-1; NCT01253707).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 80374,
                "name": "gastroesophageal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14839,
                    "pubMedId": null,
                    "title": "Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients (pts) with MET-amplified gastroesophageal junction (GEJ), gastric (G), or esophageal (E) cancer.",
                    "url": "https://ascopubs.org/doi/abs/10.1200/jco.2015.33.3_suppl.1"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10757,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Golvatinib (E7050) inhibited Met and Kdr (Vegfr2) phosphorylation, resulted in growth inhibition of lung cancer cells in culture and tumor regression in cell line xenograft models (PMID: 19832844).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1019,
                "therapyName": "Golvatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 41,
                    "pubMedId": 19832844,
                    "title": "E7050: a dual c-Met and VEGFR-2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19832844"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18787,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, OMO-1 induced tumor regression in a cell line xenograft model of MET-amplified squamous non-small cell lung cancer (Cancer Res 2018;78(13 Suppl):Abstract nr 4791).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 8846,
                "therapyName": "OMO-1",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16455,
                    "pubMedId": null,
                    "title": "OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models",
                    "url": "https://cancerres.aacrjournals.org/content/78/13_Supplement/4791"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13094,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Merestinib (LY2801653) treatment resulted in growth inhibition in patient-derived xenograft (PDX) models of MET-amplified non-small cell lung carcinoma that were resistant to Egfr inhibitors (Cancer Res 2010;70(8 Suppl):Abstract nr 3611).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1030,
                "therapyName": "Merestinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 729,
                    "pubMedId": null,
                    "title": "LY2801653, an orally available small molecule inhibitor of c-Met, demonstrated broad antitumor efficacy in patient derived xenograft models",
                    "url": "http://cancerres.aacrjournals.org/content/70/8_Supplement/3611"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9174,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the multitarget kinase inhibitor PP-121 inhibited survival of MET amplified non-small cell lung cancer cells that acquired resistance to SGX532 through activation of multiple kinase signaling pathways in culture (PMID: 26483207).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 2251,
                "therapyName": "PP-121",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6982,
                    "pubMedId": 26483207,
                    "title": "c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26483207"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1774,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, SAR125844 treatment in advanced solid tumor patients harboring a MET amplification was well-tolerated and resulted in a partial response in 17% (5/29) of patients, including patients with non-small cell lung carcinoma, and stable disease in 59% (17/29) of patients (PMID: 29145039; NCT01391533).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 2159,
                "therapyName": "SAR125844",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 2035,
                    "pubMedId": null,
                    "title": "A first-in-human (FIH) phase I study of SAR125844, a novel selective MET kinase inhibitor, in patients (pts) with advanced solid tumors: Dose escalation results.",
                    "url": "http://meetinglibrary.asco.org/content/126762-144"
                },
                {
                    "id": 10593,
                    "pubMedId": 29145039,
                    "title": "A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29145039"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13587,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma patient-derived xenograft models harboring MET amplification were sensitive to SCC244, demonstrating inhibition of tumor growth and stable disease (PMID: 29237805).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 6844,
                "therapyName": "SCC244",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11200,
                    "pubMedId": 29237805,
                    "title": "Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29237805"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17157,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, AMG 337 treatment resulted in an objective response rate of 18% (8/45, 8 partial responses) and stable disease in 36% (16/45) of patients with MET-amplified gastroesophageal adenocarcinoma (PMID: 30366938; NCT02016534).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 80375,
                "name": "gastroesophageal adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15223,
                    "pubMedId": 30366938,
                    "title": "A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30366938"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 21097,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) combined with S63845 synergistically induced killing of a lung cancer cell line harboring a MET amplification in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 9549,
                "therapyName": "Capmatinib + S63845",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20754,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, MET amplification was identified in 2 of 100 patients with non-small cell lung cancer at treatment discontinuation of Tagrisso (osimertinib) (PMID: 31839416).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18023,
                    "pubMedId": 31839416,
                    "title": "Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31839416"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15169,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, two patients with non-small cell lung cancer harboring EGFR T790M progressed after Tagrisso (osimertinib) treatment, and were found to have lost EGFR T790M and acquired a MET amplification (PMID: 30268451).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12768,
                    "pubMedId": 30268451,
                    "title": "Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30268451"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15166,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung cancer harboring EGFR amplification and EGFR T790M progressed after Tagrisso (osimertinib) treatment, and was found to have lost the EGFR mutations and acquired a MET amplification (PMID: 30268451).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12768,
                    "pubMedId": 30268451,
                    "title": "Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30268451"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4100,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with MET amplified esophageal adenocarcinoma had a partial response to AMG 337 therapy after 2 months of treatment (PMID: 26432108).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 4914,
                "name": "esophagus adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4397,
                    "pubMedId": 26432108,
                    "title": "Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16764,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, AMG 337 treatment resulted in a complete response in a patient with MET amplified esophagus adenocarcinoma at week 33 (PMID: 30425090; NCT01253707).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 4914,
                "name": "esophagus adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14840,
                    "pubMedId": 30425090,
                    "title": "Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30425090"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1650,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Emibetuzumab (LY2875358) treatment inhibited MET activation and proliferation of tumor cells with MET amplification in culture, and inhibited growth in MET-amplified tumor xenograft models (PMID: 25231402).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 803,
                "therapyName": "Emibetuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1762,
                    "pubMedId": 25231402,
                    "title": "LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25231402"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1698,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, ABT-700 demonstrated safety and preliminary efficacy in patients with MET-amplified advanced solid tumors, including a patient with ovarian cancer (J Clin Oncol 32:5s, 2014 (suppl; abstr 2507)).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 1063,
                "therapyName": "ABT-700",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1811,
                    "pubMedId": null,
                    "title": "Phase 1, open-label, dose-escalation, and expansion study of ABT-700, an anti-C-met antibody, in patients (pts) with advanced solid tumors.",
                    "url": "http://meetinglibrary.asco.org/content/134301-144"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8708,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KTN0073-IgG2 inhibited MET phosphorylation and induced MET degradation, and inhibited growth of a MET-amplified gastric cancer cell line in culture and in xenograft models (PMID: 27550450).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 4799,
                "therapyName": "KTN0073-IgG2",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6713,
                    "pubMedId": 27550450,
                    "title": "Antitumor Properties of an IgG2-Enhanced Next-Generation MET Monoclonal Antibody That Degrades Wild-Type and Mutant MET Receptors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27550450"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9179,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) inhibited tumor grow in patient-derived xenograft models of MET amplified liver cancer (PMID: 26483207).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3571,
                "name": "liver cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6982,
                    "pubMedId": 26483207,
                    "title": "c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26483207"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 985,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BEZ235 suppressed the growth of an Iressa (gefitinib)-resistant NSCLC cell line with MET amplification (PMID: 24939055).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 672,
                "therapyName": "BEZ235",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 642,
                    "pubMedId": 24939055,
                    "title": "Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24939055"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21103,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Savolitinib (AZD6094) treatment inhibited proliferation of a lung cancer cell line harboring a MET amplification in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 2161,
                "therapyName": "Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13580,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SCC244 inhibited Met activity, downstream signaling, and cell proliferation in gastric cancer cells harboring MET amplification in culture, and inhibited tumor growth in cell line xenograft models (PMID: 29237805).",
            "molecularProfile": {
                "id": 1629,
                "profileName": "MET amp"
            },
            "therapy": {
                "id": 6844,
                "therapyName": "SCC244",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11200,
                    "pubMedId": 29237805,
                    "title": "Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29237805"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3526,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastric carcinoma cell line harboring MET amplification treated with PF-04217903 eventually developed resistance due to acquisition of the fusion SND1-BRAF, in culture (PMID: 22745804).",
            "molecularProfile": {
                "id": 13346,
                "profileName": "SND1 - BRAF MET amp"
            },
            "therapy": {
                "id": 864,
                "therapyName": "PF-04217903",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3751,
                    "pubMedId": 22745804,
                    "title": "A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22745804"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3527,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a gastric cancer cell line harboring MET amplification and SND1-BRAF was sensitive to the combination of PF-04880594 and PF-0461903 in culture (PMID: 22745804).",
            "molecularProfile": {
                "id": 13346,
                "profileName": "SND1 - BRAF MET amp"
            },
            "therapy": {
                "id": 3152,
                "therapyName": "PF-0461903 + PF-04880594",
                "synonyms": null
            },
            "indication": {
                "id": 5517,
                "name": "stomach carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3751,
                    "pubMedId": 22745804,
                    "title": "A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through [corrected] MAPK activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22745804"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12869,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) inhibited the growth of gastroesophageal adenocarcinoma cells with ERBB2 (HER2) and MET amplification in culture (PMID: 25350844).",
            "molecularProfile": {
                "id": 17215,
                "profileName": "ERBB2 amp MET amp"
            },
            "therapy": {
                "id": 3440,
                "therapyName": "Crizotinib + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4944,
                "name": "gastroesophageal junction adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10818,
                    "pubMedId": 25350844,
                    "title": "Src mutation induces acquired lapatinib resistance in ERBB2-amplified human gastroesophageal adenocarcinoma models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25350844"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4090,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 and MET was resistant to Tykerb (lapatinib) in culture (PMID: 26432108).",
            "molecularProfile": {
                "id": 17215,
                "profileName": "ERBB2 amp MET amp"
            },
            "therapy": {
                "id": 787,
                "therapyName": "Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1107,
                "name": "esophageal carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4397,
                    "pubMedId": 26432108,
                    "title": "Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11555,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with ERBB2 (HER2) and MET amplification in culture (PMID: 27595477).",
            "molecularProfile": {
                "id": 17215,
                "profileName": "ERBB2 amp MET amp"
            },
            "therapy": {
                "id": 3440,
                "therapyName": "Crizotinib + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4914,
                "name": "esophagus adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9641,
                    "pubMedId": 27595477,
                    "title": "Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27595477"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4094,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma had near complete regression of the disease after 2 months of treatment with Herceptin (trastuzumab), Xalkori (crizotinib) and weekly Taxol (paclitaxel) (PMID: 26432108).",
            "molecularProfile": {
                "id": 17215,
                "profileName": "ERBB2 amp MET amp"
            },
            "therapy": {
                "id": 3442,
                "therapyName": "Crizotinib + Paclitaxel + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4397,
                    "pubMedId": 26432108,
                    "title": "Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4089,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was resistant to Xalkori (crizotinib) in culture (PMID: 26432108).",
            "molecularProfile": {
                "id": 17215,
                "profileName": "ERBB2 amp MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1107,
                "name": "esophageal carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4397,
                    "pubMedId": 26432108,
                    "title": "Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4092,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human esophageal carcinoma cell line harboring amplification of ERBB2 (HER2) and MET was sensitive to inhibition by Tykerb (lapatinib) and Xalkori (crizotinib) in culture (PMID: 26432108).",
            "molecularProfile": {
                "id": 17215,
                "profileName": "ERBB2 amp MET amp"
            },
            "therapy": {
                "id": 3440,
                "therapyName": "Crizotinib + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1107,
                "name": "esophageal carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4397,
                    "pubMedId": 26432108,
                    "title": "Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4093,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with ERBB2 (HER2) amplified gastric adenocarcinoma progressed rapidly when treated with Herceptin (trastuzumab) with Xeloda (capecitabine), Eloxatin (oxaliplatin), and Avastin (bevacizumab), and reprofiling of the tumor revealed co-amplification of MET (PMID: 26432108).",
            "molecularProfile": {
                "id": 17215,
                "profileName": "ERBB2 amp MET amp"
            },
            "therapy": {
                "id": 3441,
                "therapyName": "Bevacizumab + Capecitabine + Oxaliplatin + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4397,
                    "pubMedId": 26432108,
                    "title": "Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4084,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma did not respond to AMG 337 therapy (PMID: 26432108).",
            "molecularProfile": {
                "id": 17215,
                "profileName": "ERBB2 amp MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4397,
                    "pubMedId": 26432108,
                    "title": "Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4091,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with ERBB2 (HER2) and MET co-amplified gastric adenocarcinoma was insensitive to Herceptin (trastuzumab) and FOLFOX combination treatment (PMID: 26432108).",
            "molecularProfile": {
                "id": 17215,
                "profileName": "ERBB2 amp MET amp"
            },
            "therapy": {
                "id": 3439,
                "therapyName": "Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4397,
                    "pubMedId": 26432108,
                    "title": "Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4081,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with a MET amplified adenocarcinoma of the distal esophagus responded to AMG 337 treatment for 2 years, but developed resistance upon emergence of KRAS G12D (PMID: 26432108).",
            "molecularProfile": {
                "id": 17216,
                "profileName": "KRAS G12D MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 4914,
                "name": "esophagus adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 4397,
                    "pubMedId": 26432108,
                    "title": "Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26432108"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15165,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung cancer harboring EGFR amplification progressed after Iressa (gefitinib) treatment, and was found to have acquired MET amplification (PMID: 30268451).",
            "molecularProfile": {
                "id": 17304,
                "profileName": "EGFR amp MET amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12768,
                    "pubMedId": 30268451,
                    "title": "Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30268451"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11557,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Xalkori (crizotinib) and Tykerb (lapatinib) worked synergistically to inhibit growth of an esophageal adenocarcinoma cell line with EGFR and MET copy number gain in culture (PMID: 27595477).",
            "molecularProfile": {
                "id": 17304,
                "profileName": "EGFR amp MET amp"
            },
            "therapy": {
                "id": 3440,
                "therapyName": "Crizotinib + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4914,
                "name": "esophagus adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9641,
                    "pubMedId": 27595477,
                    "title": "Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27595477"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15168,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with non-small cell lung cancer harboring EGFR amplification progressed after Tarceva (erlotinib) treatment, and was found to have acquired a MET amplification (PMID: 30268451).",
            "molecularProfile": {
                "id": 17304,
                "profileName": "EGFR amp MET amp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12768,
                    "pubMedId": 30268451,
                    "title": "Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30268451"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15167,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, two patients with non-small cell lung cancer harboring EGFR amplification and EGFR T790M progressed after Tagrisso (osimertinib) treatment, and were found to have lost the EGFR T790M and acquired MET amplification (PMID: 30268451).",
            "molecularProfile": {
                "id": 17304,
                "profileName": "EGFR amp MET amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 12768,
                    "pubMedId": 30268451,
                    "title": "Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30268451"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9236,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M developed resistance to Tagrisso (osimertinib), and was found to have acquired high level amplification of MET (PMID: 27393507).",
            "molecularProfile": {
                "id": 18241,
                "profileName": "EGFR exon 19 del EGFR T790M MET amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7045,
                    "pubMedId": 27393507,
                    "title": "High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27393507"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9238,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring an EGFR exon 19 deletion and EGFR T790M and resistance to Tagrisso (osimertinib) following acquired MET amplification, demonstrated some improvement in symptoms with Xalkori (crizotinib) treatment (PMID: 27393507).",
            "molecularProfile": {
                "id": 18241,
                "profileName": "EGFR exon 19 del EGFR T790M MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7045,
                    "pubMedId": 27393507,
                    "title": "High MET amplification level as a resistance mechanism to osimertinib (AZD9291) in a patient that symptomatically responded to crizotinib treatment post-osimertinib progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27393507"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7503,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, JNJ-61186372 inhibited tumor growth in Tarceva (erlotinib)-resistant non-small cell lung cancer cell line xenograft models harboring an EGFR exon 19 deletion and MET amplification (PMID: 27216193).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 4491,
                "therapyName": "JNJ-61186372",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6352,
                    "pubMedId": 27216193,
                    "title": "A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27216193"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21050,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment combined with Iressa (gefitinib) induced cell death of an Iressa (gefitinib)-resistant lung cancer cell line harboring an EGFR exon 19 deletion and a MET amplification in culture, and induced tumor regression in a cell line xenograft model (PMID: 30674502).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 7415,
                "therapyName": "Capmatinib + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9531,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Gilotrif (afatinib) (PMID: 27694386).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18058,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15979,
                    "pubMedId": 30791921,
                    "title": "Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30791921"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2471,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, amplification of MET conferred resistance to Iressa (gefitinib) in non-small cell lung cancer cells harboring an EGFR exon 19 deletion mutation in culture (PMID: 17463250).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3145,
                    "pubMedId": 17463250,
                    "title": "MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17463250"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18059,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15979,
                    "pubMedId": 30791921,
                    "title": "Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30791921"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21051,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer cell line harboring an EGFR exon 19 deletion and a MET amplification demonstrated resistance to treatment with Iressa (gefitinib) in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17902,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with Iressa (gefitinib)-resistant lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated improvement in symptoms and decrease in tumor size following treatment with Tarceva (erlotinib) and Avastin (bevacizumab) (PMID: 30792648).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 1146,
                "therapyName": "Bevacizumab + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15864,
                    "pubMedId": 30792648,
                    "title": "Promising Combination Therapy with Bevacizumab and Erlotinib in an EGFR-Mutated NSCLC Patient with MET Amplification Who Showed Intrinsic Resistance to Initial EGFR-TKI Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30792648"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9532,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification was resistant to Tarceva (erlotinib) (PMID: 27694386).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18067,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Xalkori (crizotinib) alone (n=8) or in combination with EGFR TKIs (n=6) resulted in an objective response rate (ORR) of 50% (7/14, 7 partial response) and a disease control rate (DCR) of 85.7% (12/14) in patients with EGFR-mutant (L858R n=12, exon 19 deletion n=2) non-small cell lung cancer who acquired resistance to EGFR TKI through MET amplification, ORR and DCR were not significantly different between patients treated with or without EGFR TKI (PMID: 30791921).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15979,
                    "pubMedId": 30791921,
                    "title": "Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30791921"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21049,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment led to tumor stasis for more than 3 weeks in a cell line xenograft model of lung cancer harboring an EGFR exon 19 deletion and a MET amplification (PMID: 30674502).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9533,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated a near complete response when treated with the combination of Savolitinib (AZD6094) and Tagrisso (osimertinib) obtained through a Phase I trial, however, after 36 weeks presented with progression (PMID: 27694386; NCT02143466).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 2224,
                "therapyName": "Osimertinib + Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18060,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and icotinib (n=5) (PMID: 30791921).",
            "molecularProfile": {
                "id": 25627,
                "profileName": "EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15979,
                    "pubMedId": 30791921,
                    "title": "Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30791921"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7733,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MET amplified lung cancer cells harboring KRAS G12A were insensitive to SAR125844-mediated growth inhibition in culture (PMID: 25504634).",
            "molecularProfile": {
                "id": 25935,
                "profileName": "KRAS G12A MET amp"
            },
            "therapy": {
                "id": 2159,
                "therapyName": "SAR125844",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2009,
                    "pubMedId": 25504634,
                    "title": "The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25504634"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9029,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a MET-amplified lung cancer cell line harboring KRAS G12A was not sensitive to growth inhibition by AMG 337 in culture (PMID: 27196782).",
            "molecularProfile": {
                "id": 25935,
                "profileName": "KRAS G12A MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6878,
                    "pubMedId": 27196782,
                    "title": "In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27196782"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7753,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with a carcinoma of unknown primary harboring MET amplification and KRAS G12V demonstrated a durable response following treatment with Xalkori (crizotinib) (PMID: 25232318).",
            "molecularProfile": {
                "id": 25979,
                "profileName": "KRAS G12V MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 305,
                "name": "carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6473,
                    "pubMedId": 25232318,
                    "title": "Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25232318"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8802,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Tagrisso (osimertinib) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Tagrisso (osimertinib) (PMID: 27252416).",
            "molecularProfile": {
                "id": 26437,
                "profileName": "EGFR T790M MET amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6756,
                    "pubMedId": 27252416,
                    "title": "Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27252416"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9246,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis, emergence of MET amplification was identified in 26% (28/43) of EGFR T790M-positive non-small cell lung cancer patients with acquired resistance to Rociletinib (CO1686), and patients with MET amplification prior to Rociletinib (CO1686) treatment demonstrated a decreased response compared to patients without MET amplification (PMID: 27283993).",
            "molecularProfile": {
                "id": 26437,
                "profileName": "EGFR T790M MET amp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8801,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of EGFR T790M in MET-amplified lung adenocarcinoma cells resulted in resistance to Rociletinib (CO-1686) in culture, consistent with MET amplification identified in tumor samples of lung adenocarcinoma patients harboring EGFR T790M that developed resistance to Rociletinib (CO-1686) (PMID: 27252416).",
            "molecularProfile": {
                "id": 26437,
                "profileName": "EGFR T790M MET amp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 6756,
                    "pubMedId": 27252416,
                    "title": "Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27252416"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9557,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acquired amplification of MET conferred resistance to Iressa (gefitinib) in a non-small cell lung cancer cell line harboring EGFR E746_A750del in culture (PMID: 27612490).",
            "molecularProfile": {
                "id": 26798,
                "profileName": "EGFR E746_A750del MET amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7271,
                    "pubMedId": 27612490,
                    "title": "Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27612490"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9247,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, emergence of MET amplification was associated with resistance to Rociletinib (CO1686) in non-small cell lung cancer cell line xenograft models harboring EGFR E746_A750del (PMID: 27283993).",
            "molecularProfile": {
                "id": 26798,
                "profileName": "EGFR E746_A750del MET amp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9655,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of NPS-1034 to treatment with Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).",
            "molecularProfile": {
                "id": 26798,
                "profileName": "EGFR E746_A750del MET amp"
            },
            "therapy": {
                "id": 5116,
                "therapyName": "Gefitinib + NPS-1034",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7367,
                    "pubMedId": 24165158,
                    "title": "MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24165158"
                },
                {
                    "id": 7368,
                    "pubMedId": 23542356,
                    "title": "Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23542356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12148,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Capmatinib (INC280) resulted in improved survival in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).",
            "molecularProfile": {
                "id": 26798,
                "profileName": "EGFR E746_A750del MET amp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10116,
                    "pubMedId": 28961841,
                    "title": "Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961841"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12157,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Gilotrif (afatinib) did not demonstrate benefit in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification, with all treated mice demonstrating progression (PMID: 28961841).",
            "molecularProfile": {
                "id": 26798,
                "profileName": "EGFR E746_A750del MET amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 10116,
                    "pubMedId": 28961841,
                    "title": "Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961841"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9656,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of PHA-665752 and Iressa (gefitinib) overcame Iressa (gefitinib) resistance in a cell line xenograft model of non-small cell lung cancer reported to harbor EGFR E746_A750del (PMID: 23542356), which has acquired resistance to Iressa (gefitinib) due to MET amplification and over expression, resulting in tumor growth inhibition (PMID: 24165158).",
            "molecularProfile": {
                "id": 26798,
                "profileName": "EGFR E746_A750del MET amp"
            },
            "therapy": {
                "id": 5094,
                "therapyName": "Gefitinib + PHA-665752",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7367,
                    "pubMedId": 24165158,
                    "title": "MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24165158"
                },
                {
                    "id": 7368,
                    "pubMedId": 23542356,
                    "title": "Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23542356"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12150,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with Capmatinib (INC280) plus Gilotrif (afatinib) resulted in improved survival with no evidence of tumor 300 days post-transplantation in patient-derived xenograft (PDX) models derived from the brain metastasis of a lung adenocarcinoma patient with EGFR E746_A750del (referred to as K745_A750delinsK) and high level MET amplification (PMID: 28961841).",
            "molecularProfile": {
                "id": 26798,
                "profileName": "EGFR E746_A750del MET amp"
            },
            "therapy": {
                "id": 6313,
                "therapyName": "Afatinib + Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10116,
                    "pubMedId": 28961841,
                    "title": "Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961841"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12147,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with metastatic lung adenocarcinoma harboring EGFR E746_A750del (referred to as K745_A750delinsK) and T790M demonstrated an initial response, but subsequent progression, of the brain metastasis following Tagrisso (osimertinib) treatment, and analysis of the brain metastasis showed loss of EGFR T790M as well as acquisition of high-level MET amplification, and resistance to Tagrisso (osimertinib) was recapitulated in a patient-derived xenograft (PDX) model (PMID: 28961841).",
            "molecularProfile": {
                "id": 26798,
                "profileName": "EGFR E746_A750del MET amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10116,
                    "pubMedId": 28961841,
                    "title": "Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28961841"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9248,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in non-small cell lung cancer cell line harboring EGFR E746_A750del and MET amplification in culture (PMID: 27283993).",
            "molecularProfile": {
                "id": 26798,
                "profileName": "EGFR E746_A750del MET amp"
            },
            "therapy": {
                "id": 4962,
                "therapyName": "Crizotinib + Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20705,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, MET amplification was detected in non-small cell lung cancer patients harboring EGFR L858R with acquired resistance to Tagrisso (osimertinib) therapy (PMID: 31911548).",
            "molecularProfile": {
                "id": 26799,
                "profileName": "EGFR L858R MET amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17999,
                    "pubMedId": 31911548,
                    "title": "Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31911548"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18484,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring EGFR L858R and MET amplification demonstrated primary resistance to second line treatment with Iressa (gefitinib) (PMID: 30797494).",
            "molecularProfile": {
                "id": 26799,
                "profileName": "EGFR L858R MET amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16266,
                    "pubMedId": 30797494,
                    "title": "Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30797494"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18065,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and icotinib (n=5) (PMID: 30791921).",
            "molecularProfile": {
                "id": 26799,
                "profileName": "EGFR L858R MET amp"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15979,
                    "pubMedId": 30791921,
                    "title": "Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30791921"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18483,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring EGFR L858R and MET amplification with primary resistance to Iressa (gefitinib) demonstrated a 73% reduction in the right lung lesions after 4 weeks and almost complete reduction by 8 weeks, and maintained progression-free survival for 16.8 months following treatment with the combination of Xalkori (crizotinib) and Iressa (gefitinib) (PMID: 30797494).",
            "molecularProfile": {
                "id": 26799,
                "profileName": "EGFR L858R MET amp"
            },
            "therapy": {
                "id": 7668,
                "therapyName": "Crizotinib + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16266,
                    "pubMedId": 30797494,
                    "title": "Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30797494"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18066,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Xalkori (crizotinib) alone (n=8) or in combination with EGFR TKIs (n=6) resulted in an objective response rate (ORR) of 50% (7/14, 7 partial response) and a disease control rate (DCR) of 85.7% (12/14) in patients with EGFR-mutant (L858R n=12, exon 19 deletion n=2) non-small cell lung cancer who acquired resistance to EGFR TKI through MET amplification, ORR and DCR were not significantly different between patients treated with or without EGFR TKI (PMID: 30791921).",
            "molecularProfile": {
                "id": 26799,
                "profileName": "EGFR L858R MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15979,
                    "pubMedId": 30791921,
                    "title": "Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30791921"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9249,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Rociletinib (CO-1686) and Xalkori (crizotinib) overcame resistance to Rociletinib (CO-1686) in a patient-derived xenograft model of non-small cell lung cancer harboring EGFR L858R and MET amplification, resulting in tumor growth inhibition (PMID: 27283993).",
            "molecularProfile": {
                "id": 26799,
                "profileName": "EGFR L858R MET amp"
            },
            "therapy": {
                "id": 4962,
                "therapyName": "Crizotinib + Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18062,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).",
            "molecularProfile": {
                "id": 26799,
                "profileName": "EGFR L858R MET amp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15979,
                    "pubMedId": 30791921,
                    "title": "Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30791921"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18063,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, MET amplification was identified as an acquired resistance mechanism in non-small cell lung cancer patients harboring EGFR mutations (L858R n=16, exon 19 deletion n=2) whose disease progressed on EGFR tyrosine kinase inhibitor treatment including Tarceva (erlotinib) (n=3), Iressa (gefitinib) (n=10), and Conmana (Icotinib) (n=5) (PMID: 30791921).",
            "molecularProfile": {
                "id": 26799,
                "profileName": "EGFR L858R MET amp"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15979,
                    "pubMedId": 30791921,
                    "title": "Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30791921"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16633,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion and MET amplification demonstrated a near complete response when treated with the combination of Savolitinib (AZD6094) and Tagrisso (osimertinib) obtained through a Phase I trial, however, after 36 weeks presented with progression and MET D1228V was identified as an acquired mutation (PMID: 27694386; NCT02143466).",
            "molecularProfile": {
                "id": 26887,
                "profileName": "EGFR exon 19 del MET D1228V MET amp"
            },
            "therapy": {
                "id": 2224,
                "therapyName": "Osimertinib + Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9534,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring an EGFR exon 19 deletion, MET amplification, and MET D1228V demonstrated a strong response to the combination of Tarceva (erlotinib) and Cometriq (Cabometyx, cabozantinib), resulting in reduced tumor size and continued clinical benefit 5 months after the start of therapy (PMID: 27694386).",
            "molecularProfile": {
                "id": 26887,
                "profileName": "EGFR exon 19 del MET D1228V MET amp"
            },
            "therapy": {
                "id": 1255,
                "therapyName": "Cabozantinib + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7247,
                    "pubMedId": 27694386,
                    "title": "Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27694386"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9579,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of BI 836845 and PHA-665752 inhibited AKT and ERK signaling and induced apoptosis in lung adenocarcinoma cell lines harboring EGFR E746_A750del and MET amplification with acquired resistance to Iressa (geftinib) and PHA-665752 combination therapy due to activation of IGF1R signaling (PMID: 27612490).",
            "molecularProfile": {
                "id": 26907,
                "profileName": "EGFR E746_A750del IGF1R pos MET amp"
            },
            "therapy": {
                "id": 5096,
                "therapyName": "PHA-665752 + Xentuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7271,
                    "pubMedId": 27612490,
                    "title": "Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27612490"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9574,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, lung adenocarcinoma cell lines harboring EGFR E746_A750del and MET amplification acquired resistance to treatment with the combination of Iressa (gefitinib) and PHA-665752 due to bypass activation of IGF1R in culture (PMID: 27612490).",
            "molecularProfile": {
                "id": 26907,
                "profileName": "EGFR E746_A750del IGF1R pos MET amp"
            },
            "therapy": {
                "id": 5094,
                "therapyName": "Gefitinib + PHA-665752",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7271,
                    "pubMedId": 27612490,
                    "title": "Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27612490"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9577,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Linsitinib (OSI-906) in combination with Iressa (gefitinib) and PHA-665752 decreased proliferation of lung adenocarcinoma cell lines harboring EGFR E746_A750del and MET amplification, with acquired resistance to Iressa (gefitinib) and PHA-665752 combination therapy due to activation of IGF1R signaling (PMID: 27612490).",
            "molecularProfile": {
                "id": 26907,
                "profileName": "EGFR E746_A750del IGF1R pos MET amp"
            },
            "therapy": {
                "id": 5095,
                "therapyName": "Gefitinib + Linsitinib + PHA-665752",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7271,
                    "pubMedId": 27612490,
                    "title": "Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27612490"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9658,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of NPS-1034 and Iressa (gefitinib) inhibited EGFR, MET, and AXL activity and decreased viability of an Iressa (gefitinib)-resistant non-small cell lung cancer cell line that harbors EGFR E746_A750del and EGFR T790M, as well as MET amplification and over expression of AXL, in culture (PMID: 24165158).",
            "molecularProfile": {
                "id": 26948,
                "profileName": "AXL over exp EGFR E746_E749del EGFR T790M MET amp"
            },
            "therapy": {
                "id": 5116,
                "therapyName": "Gefitinib + NPS-1034",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7367,
                    "pubMedId": 24165158,
                    "title": "MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24165158"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9659,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of NPS-1034 and Tarceva (erlotinib inhibited EGFR, MET, and AXL activity and decreased viability of a Tarceva (erlotinib)-resistant non-small cell lung cancer cell line that harbors EGFR E746_A750del and EGFR T790M, as well as MET amplification and over expression of AXL, in culture (PMID: 24165158).",
            "molecularProfile": {
                "id": 26948,
                "profileName": "AXL over exp EGFR E746_E749del EGFR T790M MET amp"
            },
            "therapy": {
                "id": 5117,
                "therapyName": "Erlotinib + NPS-1034",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7367,
                    "pubMedId": 24165158,
                    "title": "MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24165158"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11535,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Xalkori (crizotinib) treatment resulted in complete tumor regression in transplant models of TP53-null-luminal breast cancer harboring MET amplification (PMID: 27149990).",
            "molecularProfile": {
                "id": 28118,
                "profileName": "MET amp TP53 del"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1612,
                "name": "breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9604,
                    "pubMedId": 27149990,
                    "title": "Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27149990"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11788,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring MET deletion exon 14 and MET amplification demonstrated resistance to Xalkori (crizotinib), and the patient was found to have acquired MET Y1230H, MET D1228N, MET Y1230S, and MET G1163R (PMID: 28765324).",
            "molecularProfile": {
                "id": 28219,
                "profileName": "MET del exon14 MET G1163R MET D1228N MET Y1230H MET Y1230S MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11740,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring MET deletion exon 14 responded to Xalkori (crizotinib), demonstrating a near complete response at 3 months, however, after 9 months progression ensued and a re-biospy identified MET del exon14, MET amplification, MET D1228N, MET Y1230H, MET Y1230S, and MET G1163R (PMID: 28522754).",
            "molecularProfile": {
                "id": 28219,
                "profileName": "MET del exon14 MET G1163R MET D1228N MET Y1230H MET Y1230S MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9758,
                    "pubMedId": 28522754,
                    "title": "MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28522754"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11786,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient co-harboring MET exon 14 deletion and MET amp was sensitive to Xalkori (crizotinib), demonstrating a partial response for 8 months (PMID: 28765324).",
            "molecularProfile": {
                "id": 28229,
                "profileName": "MET del exon14 MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11767,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a lung cancer patient-derived xenograft (PDX) model harboring MET amplification and MET exon 14 deletion demonstrated tumor regression when treated with Glesatinib (MGCD265) (PMID: 28765324).",
            "molecularProfile": {
                "id": 28229,
                "profileName": "MET del exon14 MET amp"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13584,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung carcinoma patient derived xenograft (PDX) models co-harboring MET amplification and MET deletion of exon 14 were sensitive to SCC244 treatment, demonstrating a complete response in four and a partial response in another four (PMID: 29237805).",
            "molecularProfile": {
                "id": 28229,
                "profileName": "MET del exon14 MET amp"
            },
            "therapy": {
                "id": 6844,
                "therapyName": "SCC244",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11200,
                    "pubMedId": 29237805,
                    "title": "Preclinical Evaluation of SCC244 (Glumetinib), a Novel, Potent, and Highly Selective Inhibitor of c-Met in MET-dependent Cancer Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29237805"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16839,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TPX-0022 treatment resulted in tumor regression in patient-derived xenograft (PDX) models of lung cancer harboring MET amplification and MET exon 14 deletion (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1321).",
            "molecularProfile": {
                "id": 28229,
                "profileName": "MET del exon14 MET amp"
            },
            "therapy": {
                "id": 8205,
                "therapyName": "TPX-0022",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14951,
                    "pubMedId": null,
                    "title": "TPX-0022, a polypharmacology inhibitor of MET/CSF1R/SRC for treatment of cancers with abnormal HGF/MET signaling.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9564,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring a MET exon 14 skipping mutation and MET amplification demonstrated a complete response via PERCIST criteria when treated with Cometriq (Cabometyx, cabozantinib) (PMID: 25971939).",
            "molecularProfile": {
                "id": 28229,
                "profileName": "MET del exon14 MET amp"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7281,
                    "pubMedId": 25971939,
                    "title": "Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25971939"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12329,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Glesatinib (MGCD265) treatment resulted in tumor regression in patient-derived xenograft (PDX) models of non-small cell lung cancer harboring deletion of MET exon 14 and varying degrees of MET amplification (PMID: 28765324).",
            "molecularProfile": {
                "id": 28229,
                "profileName": "MET del exon14 MET amp"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11787,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient previously harboring MET amp, MET deletion exon 14, MET D1228N, MET Y1230H, MET Y1230S, and MET G1163R demonstrated a decrease in lesion size when treated with Glesatinib (MGCD265), however, progression ensued and plasma testing indicated the patient lost Y1230H and Y1230S, but acquired MET L1195V (PMID: 28765324).",
            "molecularProfile": {
                "id": 28246,
                "profileName": "MET del exon14 MET G1163R MET L1195V MET D1228N MET amp"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 9757,
                    "pubMedId": 28765324,
                    "title": "Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28765324"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12266,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD4547 and Xalkori (crizotinib) synergistically inhibited proliferation of FGFR1 amplified lung cancer cells that acquired resistance to AZD4547 through MET amplification in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28587,
                "profileName": "FGFR1 amp MET amp"
            },
            "therapy": {
                "id": 6398,
                "therapyName": "AZD4547 + Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12264,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MET amplification was identified as the mechanism mediating acquired AZD4547 resistance in a FGFR1 amplified lung cancer cell line in culture (PMID: 27429073).",
            "molecularProfile": {
                "id": 28587,
                "profileName": "FGFR1 amp MET amp"
            },
            "therapy": {
                "id": 654,
                "therapyName": "AZD4547",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 9936,
                    "pubMedId": 27429073,
                    "title": "Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27429073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12257,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, MET amplification was detected in a squamous cell lung cancer patient harboring FGFR1 amplification whose disease relapsed after 17 months of BGJ398 treatment, supporting a role of MET amplification in drug resistance in FGFR1-amplified lung cancer (PMID: 28630215).",
            "molecularProfile": {
                "id": 28587,
                "profileName": "FGFR1 amp MET amp"
            },
            "therapy": {
                "id": 674,
                "therapyName": "BGJ398",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10196,
                    "pubMedId": 28630215,
                    "title": "Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28630215"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15164,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, Xalkori (crizotinib) treatment resulted in partial response (PR) in 50% (4/8) of patients with EGFR mutant non-small cell lung cancer that acquired MET amplification after EGFR TKI therapy, although the response was short-lived, with a median progression-free survival of 3.5 months in patients achieved PR (PMID: 30268451).",
            "molecularProfile": {
                "id": 28588,
                "profileName": "EGFR mut MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 12768,
                    "pubMedId": 30268451,
                    "title": "Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30268451"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12244,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, amplification of MET was identified in a lung adenocarcinoma cell line harboring EGFR mutation that acquired resistance to Tarceva (erlotinib) in culture (PMID: 28630215).",
            "molecularProfile": {
                "id": 28588,
                "profileName": "EGFR mut MET amp"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 10196,
                    "pubMedId": 28630215,
                    "title": "Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28630215"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15079,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, Capmatinib (INC280) and Iressa (gefitinib) combination treatment resulted in an objective response rate of 27% (43/161) in non-small cell lung cancer patients harboring EGFR mutations and MET dysregulation (amplification or overexpression), with an objective response rate of 47% in Phase II patients with a MET gene copy number greater than 6 (PMID: 30156984).",
            "molecularProfile": {
                "id": 28588,
                "profileName": "EGFR mut MET amp"
            },
            "therapy": {
                "id": 7415,
                "therapyName": "Capmatinib + Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12626,
                    "pubMedId": 30156984,
                    "title": "Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30156984"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17247,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial (TATTON), combination of Tagrisso (osimertinib) and Savolitinib (AZD6094) resulted in an objective response rate (ORR) of 48% (66/138), a disease control rate (DCR) of 83% (115/138), and a median progression-free survival (mPFS) of 7.6 months in patients with EGFR-mutant, MET-amplified non-small cell lung cancer after progression on EGFR inhibitors, and an ORR of 64% (23/36), DCR of 92% (33/36), a mPFS of 9.1 months in EGFR T790M-negative patients (PMID: 32027846; NCT02143466).",
            "molecularProfile": {
                "id": 28588,
                "profileName": "EGFR mut MET amp"
            },
            "therapy": {
                "id": 2224,
                "therapyName": "Osimertinib + Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17906,
                    "pubMedId": 32027846,
                    "title": "Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32027846"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12245,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Tarceva (erlotinib) and EMD 1214063 synergistically inhibited growth of lung carcinoma cells harboring EGFR mutation and Met amplification in culture (PMID: 28630215).",
            "molecularProfile": {
                "id": 28588,
                "profileName": "EGFR mut MET amp"
            },
            "therapy": {
                "id": 6373,
                "therapyName": "EMD 1214063 + Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10196,
                    "pubMedId": 28630215,
                    "title": "Mechanisms of Primary Drug Resistance in FGFR1-Amplified Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28630215"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12372,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SYM015 treatment resulted in tumor growth inhibition in patient-derived xenograft (PDX) models of MET-amplified lung cancer harboring EGFR activating mutations (PMID: 28679766).",
            "molecularProfile": {
                "id": 28681,
                "profileName": "EGFR act mut MET amp"
            },
            "therapy": {
                "id": 4322,
                "therapyName": "SYM015",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10340,
                    "pubMedId": 28679766,
                    "title": "Sym015: A Highly Efficacious Antibody Mixture against MET-Amplified Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28679766"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12893,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "n a clinical study (AMNESIA-1), assessment of pre-treatment tumor samples from ERBB2 (HER2)-positive (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) gastric or gastroesophageal cancer patients identified MET R988C and amplification of MET in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).",
            "molecularProfile": {
                "id": 29000,
                "profileName": "ERBB2 over exp MET R988C MET amp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10846,
                    "pubMedId": 29208673,
                    "title": "Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29208673"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12890,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study (AMNESIA-1), assessment of pre-treatment tissue from ERBB2 (HER2)-positive gastric or gastroesophageal cancer patients (defined as HER2 IHC 3+ or HER2 IHC 2+/ISH+) identified MET amplification in 1 patient demonstrating primary resistance to Herceptin (trastuzumab) (PMID: 29208673).",
            "molecularProfile": {
                "id": 29001,
                "profileName": "ERBB2 over exp MET amp"
            },
            "therapy": {
                "id": 947,
                "therapyName": "Trastuzumab",
                "synonyms": null
            },
            "indication": {
                "id": 10534,
                "name": "stomach cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 10846,
                    "pubMedId": 29208673,
                    "title": "Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29208673"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13578,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in rapid initial response in a patient with non-small cell lung cancer with brain metastasis harboring KLC1-ALK fusion and MET amplification (PMID: 28607809).",
            "molecularProfile": {
                "id": 29158,
                "profileName": "KLC1 - ALK MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11199,
                    "pubMedId": 28607809,
                    "title": "Rapid response of brain metastasis to crizotinib in a patient with KLC1-ALK fusion and MET gene amplification positive non-small cell lung cancer: a case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28607809"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13840,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring an ALK rearrangement who developed resistance to Alecensa (alectinib) likely due to acquisition of MET amplification, responded well to treatment with Xalkori (crizotinib), demonstrating a radiological response after 12 days (PMID: 24128725, PMID: 24518097).",
            "molecularProfile": {
                "id": 29713,
                "profileName": "ALK rearrange MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11314,
                    "pubMedId": 24128725,
                    "title": "Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24128725"
                },
                {
                    "id": 11315,
                    "pubMedId": 24518097,
                    "title": "Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24518097"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13837,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient harboring an ALK rearrangement developed resistance to Alecensa (alectinib) treatment, and subsequently was found to harbor amplification of MET (PMID: 24128725, PMID: 24518097).",
            "molecularProfile": {
                "id": 29713,
                "profileName": "ALK rearrange MET amp"
            },
            "therapy": {
                "id": 698,
                "therapyName": "Alectinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11314,
                    "pubMedId": 24128725,
                    "title": "Dramatic response to crizotinib in an ALK-positive adenocarcinoma patient with disseminated intravascular coagulation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24128725"
                },
                {
                    "id": 11315,
                    "pubMedId": 24518097,
                    "title": "Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor?",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24518097"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13931,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR exon 19 deletion treated with Tagrisso (osimertinib) showed progression after 16 months, and was subsequently found to have acquired BRAF V600E and MET amplification (PMID: 29596911).",
            "molecularProfile": {
                "id": 29877,
                "profileName": "BRAF V600E EGFR exon 19 del MET amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 11362,
                    "pubMedId": 29596911,
                    "title": "Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29596911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14391,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a glioblastoma patient harboring amplifications in CD274, PDCD1LG2, JAK2, MET, and MDM2 was sensitive to the combined therapy of Opdivo (nivolumab) and Cometriq (cabozantinib), demonstrating a partial response at four weeks (PMID: 29902298).",
            "molecularProfile": {
                "id": 29995,
                "profileName": "CD274 amp JAK2 amp MDM2 amp MET amp PDCD1LG2 amp"
            },
            "therapy": {
                "id": 2067,
                "therapyName": "Cabozantinib + Nivolumab",
                "synonyms": null
            },
            "indication": {
                "id": 3068,
                "name": "glioblastoma multiforme",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11631,
                    "pubMedId": 29902298,
                    "title": "Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29902298"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14447,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M progressed after 19 months on Tagrisso (osimertinib), and was found to have acquired MET amplification (PMID: 29128427).",
            "molecularProfile": {
                "id": 30017,
                "profileName": "EGFR T790M EGFR L858R MET amp"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11634,
                    "pubMedId": 29128427,
                    "title": "Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29128427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14446,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a lung adenocarcinoma patient with EGFR L858R, EGFR T790M, and MET amplification demonstrated a partial response in her lung lesions and an approximately 90% reduction in the retroperitoneal lymph node and right adrenal gland, and progression-free survival lasting 3 months following treatment with the combination of Tagrisso (osimertinib) and Xalkori (crizotinib) (PMID: 29128427).",
            "molecularProfile": {
                "id": 30017,
                "profileName": "EGFR T790M EGFR L858R MET amp"
            },
            "therapy": {
                "id": 4958,
                "therapyName": "Crizotinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11634,
                    "pubMedId": 29128427,
                    "title": "Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29128427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14448,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M and MET amplification demonstrated progressive disease after 3 months of treatment with the combination of Tagrisso (osimertinib) and Xalkori (crizotinib) and was found to have acquired 4 MET mutations: MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y (PMID: 29128427).",
            "molecularProfile": {
                "id": 30018,
                "profileName": "EGFR T790M EGFR L858R MET D1228H MET D1228N MET Y1230H MET D1231Y MET amp"
            },
            "therapy": {
                "id": 4958,
                "therapyName": "Crizotinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11634,
                    "pubMedId": 29128427,
                    "title": "Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29128427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14449,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R and EGFR T790M, MET amplification and MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y demonstrated initial symptomatic improvement, decreased pleural effusion, and lung nodule shrinkage following treatment with the combination of Cometriq (Cabometyx, cabozantinib) and Tagrisso (osimertinib) (PMID: 29128427).",
            "molecularProfile": {
                "id": 30018,
                "profileName": "EGFR T790M EGFR L858R MET D1228H MET D1228N MET Y1230H MET D1231Y MET amp"
            },
            "therapy": {
                "id": 7090,
                "therapyName": "Cabozantinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "unknown",
            "references": [
                {
                    "id": 11634,
                    "pubMedId": 29128427,
                    "title": "Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29128427"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 14450,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung adenocarcinoma harboring EGFR L858R, EGFR T790M, MET amplification, MET D1228H, MET D1228N, MET Y1230H, and MET D1231Y demonstrated initial symptomatic improvement and lung nodule shrinkage following treatment Cometriq (Cabometyx, cabozantinib) and Tagrisso (osimertinib) in combination, but progressed after 1 month and was found to have lost MET D1228H, MET D1228N, and MET Y1230H, and to have an increased allele fraction of MET D1231Y (PMID: 29128427).",
            "molecularProfile": {
                "id": 30020,
                "profileName": "EGFR T790M EGFR L858R MET D1231Y MET amp"
            },
            "therapy": {
                "id": 7090,
                "therapyName": "Cabozantinib + Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11634,
                    "pubMedId": 29128427,
                    "title": "Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR-Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29128427"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15721,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, MET amplification was identified together with a pre-existing ALK I1171N at disease progression while on Alunbrig (brigatinib) treatment in a patient with ALK-positive non-small cell lung cancer (PMID: 29935304).",
            "molecularProfile": {
                "id": 31176,
                "profileName": "ALK rearrange ALK I1171N MET amp"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11688,
                    "pubMedId": 29935304,
                    "title": "Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29935304"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15806,
            "approvalStatus": "Clinical Study - Cohort",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective analysis of a Phase I and a Phase II trial, MET amplification was identified at disease progression in 26% (11/43) of patients with non-small cell lung cancer harboring both EGFR T790M and another EGFR activating mutation (exon 19 deletion, 70%; L858R, 28%) treated with Rociletinib (CO-1686), conversely, preexisting MET, ERBB2 (HER2), or EGFR amplification were more common in patients with primary resistance to Rociletinib (CO-1686) (PMID: 27283993; NCT01526928, NCT02147990).",
            "molecularProfile": {
                "id": 31227,
                "profileName": "EGFR T790M EGFR act mut MET amp"
            },
            "therapy": {
                "id": 1003,
                "therapyName": "Rociletinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 7047,
                    "pubMedId": 27283993,
                    "title": "Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27283993"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16590,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with BRAF V600E colorectal cancer developed progressive disease after achieving stable disease for 32 weeks with Vectibix (panitumumab) and Zelboraf (vemurafenib) combination treatment, KRAS and MET amplification were identified as acquired alterations at the time of progression (PMID: 28951457).",
            "molecularProfile": {
                "id": 31707,
                "profileName": "BRAF V600E KRAS amp MET amp"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14634,
                    "pubMedId": 28951457,
                    "title": "Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28951457"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16631,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, emergence of MET amplification was detected in colorectal cancer cells harboring BRAF V600E that acquired resistance to Alpelisib (BYL719), Erbitux (cetuximab), and Braftovi (encorafenib) combination treatment in culture (PMID: 27325282).",
            "molecularProfile": {
                "id": 31714,
                "profileName": "BRAF V600E MET amp"
            },
            "therapy": {
                "id": 1917,
                "therapyName": "Alpelisib + Cetuximab + Encorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6560,
                    "pubMedId": 27325282,
                    "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8153,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with microsatellite-stable mucinous rectal cancer harboring BRAF V600E eventually developed resistance to Vectibix (panitumumab) and Zelboraf (vemurafenib) combination therapy, potentially due to acquiring amplification of MET (PMID: 27325282).",
            "molecularProfile": {
                "id": 31714,
                "profileName": "BRAF V600E MET amp"
            },
            "therapy": {
                "id": 1717,
                "therapyName": "Panitumumab + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3709,
                "name": "rectum mucinous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 6560,
                    "pubMedId": 27325282,
                    "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8152,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with microsatellite-stable mucinous rectal cancer harboring BRAF V600E and acquired MET amplification responded to the combination treatment of Xalkori (crizotinib) and Zelboraf (vemurafenib), resulting in a rapid clinical and metabolic response (PMID: 27325282).",
            "molecularProfile": {
                "id": 31714,
                "profileName": "BRAF V600E MET amp"
            },
            "therapy": {
                "id": 4648,
                "therapyName": "Crizotinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3709,
                "name": "rectum mucinous adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6560,
                    "pubMedId": 27325282,
                    "title": "MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27325282"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16681,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a gastric adenocarcinoma patient-derived xenograft (PDX) model with amplification of EGFR, ERBB2 (HER2), and MET demonstrated resistance to treatment with AMG 337 (PMID: 30463996; NCT01522768).",
            "molecularProfile": {
                "id": 31753,
                "profileName": "EGFR amp ERBB2 amp MET amp"
            },
            "therapy": {
                "id": 1064,
                "therapyName": "AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14704,
                    "pubMedId": 30463996,
                    "title": "EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30463996"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16680,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a metastatic gastric adenocarcinoma patient with co-amplification of EGFR and ERBB2 (HER2) who initially responded to Gilotrif (afatinib) treatment progressed at 12 weeks and was found to have acquired amplification of MET in the progressing sites, which was subsequently confirmed to be associated with resistance via a patient-derived xenograft (PDX) model treated with Gilotrif (afatinib) (PMID: 30463996; NCT01522768).",
            "molecularProfile": {
                "id": 31753,
                "profileName": "EGFR amp ERBB2 amp MET amp"
            },
            "therapy": {
                "id": 623,
                "therapyName": "Afatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 14704,
                    "pubMedId": 30463996,
                    "title": "EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30463996"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16682,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, preclinical analysis of a gastric adenocarcinoma patient-derived xenograft (PDX) model with amplification of EGFR, ERBB2 (HER2), and MET demonstrated tumor regression when treated with a combination of Gilotrif (afatinib) and AMG 337 (PMID: 30463996; NCT01522768).",
            "molecularProfile": {
                "id": 31753,
                "profileName": "EGFR amp ERBB2 amp MET amp"
            },
            "therapy": {
                "id": 8125,
                "therapyName": "Afatinib + AMG 337",
                "synonyms": null
            },
            "indication": {
                "id": 3717,
                "name": "gastric adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14704,
                    "pubMedId": 30463996,
                    "title": "EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30463996"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16870,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, MET D1228N was identified as an acquired mutation at disease progression in a patient with triple-receptor negative breast cancer harboring a 30-fold amplification of MET, after initial response to Xalkori (crizotinib) treatment (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1317).",
            "molecularProfile": {
                "id": 32092,
                "profileName": "MET D1228N MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14988,
                    "pubMedId": null,
                    "title": "Exceptional responses to crizotinib in breast cancer patients with somatic MET and ROS1 alterations.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16871,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Cometriq (Cabometyx, cabozantinib) treatment resulted in stable diseases in a patient with triple-receptor negative breast cancer harboring a 30-fold amplification of MET whom developed resistance to Xalkori (crizotinib) after acquiring MET D1228N (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1317).",
            "molecularProfile": {
                "id": 32092,
                "profileName": "MET D1228N MET amp"
            },
            "therapy": {
                "id": 998,
                "therapyName": "Cabozantinib",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14988,
                    "pubMedId": null,
                    "title": "Exceptional responses to crizotinib in breast cancer patients with somatic MET and ROS1 alterations.",
                    "url": "https://www.aacr.org/Documents/AACR_2019_Proceedings.pdf"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18041,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in rapid clinical improvement and a complete response 1 month after treatment in a patient with adenocarcinoma of unknown primary harboring MET amplification and a NTRK1 mutation (c.339-2 A>C), with a progression-free survival of 8.5 months and an overall survival of 10.0 months (PMID: 31213843).",
            "molecularProfile": {
                "id": 32950,
                "profileName": "MET amp NTRK1 mut"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 299,
                "name": "adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15970,
                    "pubMedId": 31213843,
                    "title": "Complete response to crizotinib in a metastatic adenocarcinoma of unknown primary harboring MET amplification and NTRK1 co-occurring mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31213843"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18122,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SHR-A1307 resulted in the inhibition of tumor growth in the EGFR overexpressing and MET amplified patient-derived xenograft models (PDX) of non-small cell lung cancer (PMID: 30962319).",
            "molecularProfile": {
                "id": 32966,
                "profileName": "EGFR over exp MET amp"
            },
            "therapy": {
                "id": 8671,
                "therapyName": "SHR-A1307",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 16007,
                    "pubMedId": 30962319,
                    "title": "Discovery of A Novel EGFR-Targeting Antibody-Drug Conjugate, SHR-A1307, for the Treatment of Solid Tumors Resistant or Refractory to Anti-EGFR Therapies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30962319"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21137,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells with MET amplification demonstrated resistance to treatment with Capmatinib (INC280) and subsequently, were found to have increased expression of EGFR in culture (PMID: 30309221).",
            "molecularProfile": {
                "id": 32966,
                "profileName": "EGFR over exp MET amp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18419,
                    "pubMedId": 30309221,
                    "title": "Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30309221"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21131,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells with MET amplification and over expression of EGFR demonstrated sensitivity to the combination therapy of Piqray (alpelisib) and Capmatinib (INC280) in culture, resulting in decreased cell proliferation (PMID: 30309221).",
            "molecularProfile": {
                "id": 32966,
                "profileName": "EGFR over exp MET amp"
            },
            "therapy": {
                "id": 6313,
                "therapyName": "Afatinib + Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18419,
                    "pubMedId": 30309221,
                    "title": "Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30309221"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18724,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with cholangiocarcinoma harboring PLEKHA6-NTRK1 and MET amplification demonstrated resistance to treatment with LOXO-195 (PMID: 31406350).",
            "molecularProfile": {
                "id": 33524,
                "profileName": "PLEKHA6 - NTRK1 MET amp"
            },
            "therapy": {
                "id": 5917,
                "therapyName": "LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19107,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with cholangiocarcinoma harboring PLEKHA6-NTRK1 and MET amplification demonstrated tumor shrinkage at 8 weeks and disease control for 4.5 months when treated with the combination therapy of Xalkori (crizotinib) and LOXO-195, and subsequent cell-free DNA testing showed a loss of PLEKHA6-NTRK1 and MET amplfication (PMID: 31406350).",
            "molecularProfile": {
                "id": 33524,
                "profileName": "PLEKHA6 - NTRK1 MET amp"
            },
            "therapy": {
                "id": 8913,
                "therapyName": "Crizotinib + LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18722,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with cholangiocarcinoma harboring PLEKHA6-NTRK1 developed resistance to Rozlytrek (entrectinib) and was subsequently found to have acquired MET amplification (PMID: 31406350).",
            "molecularProfile": {
                "id": 33524,
                "profileName": "PLEKHA6 - NTRK1 MET amp"
            },
            "therapy": {
                "id": 1455,
                "therapyName": "Entrectinib",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19109,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with cholangiocarcinoma harboring PLEKHA6-NTRK1 and MET amplification initially demonstrated sensitivity to the combination therapy of Xalkori (crizotinib) and LOXO-195, but progressed after 4.5 months and was found to have acquired 13 new MET missense mutations, MET D1228H, MET D1228N, MET Y1230H, MET Y1230S, MET Y1230N, MET D1228Y, MET G1090S, MET G1090A, MET R1227K, MET D1213H, MET 1195V, MET Y1230C, and MET V1092I (PMID: 31406350).",
            "molecularProfile": {
                "id": 33935,
                "profileName": "PLEKHA6 - NTRK1 MET G1090A MET G1090S MET V1092I MET L1195V MET D1213H MET R1227K MET D1228H MET D1228N MET D1228Y MET Y1230C MET Y1230H MET Y1230N MET Y1230S MET amp"
            },
            "therapy": {
                "id": 8913,
                "therapyName": "Crizotinib + LOXO-195",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16397,
                    "pubMedId": 31406350,
                    "title": "Resistance to TRK inhibition mediated by convergent MAPK pathway activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31406350"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19721,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung squamous cell carcinoma harboring EGFR S752_I759del and de novo MET amplification had primary resistance to icotinib treatment, demonstrating increased tumor size and metastasis after 3 weeks of treatment (PMID: 31131689).",
            "molecularProfile": {
                "id": 34468,
                "profileName": "EGFR S752_I759del MET amp"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17525,
                    "pubMedId": 31131689,
                    "title": "De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31131689"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19722,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with lung squamous cell carcinoma harboring EGFR S752_I759del and de novo MET amplification with primary resistance to Conmana (Icotinib) treatment demonstrated a decrease in tumor size following treatment with single-agent Xalkori (crizotinib) (PMID: 31131689).",
            "molecularProfile": {
                "id": 34468,
                "profileName": "EGFR S752_I759del MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3907,
                "name": "lung squamous cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17525,
                    "pubMedId": 31131689,
                    "title": "De novo MET amplification promotes intrinsic resistance to first-generation EGFR tyrosine kinase inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31131689"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19757,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (METROS), Xalkori (crizotinib) treatment resulted in a partial response in a patient with pre-treated non-small cell lung cancer harboring MET amplification and KRAS G13D (PMID: 31416808; NCT02499614).",
            "molecularProfile": {
                "id": 34500,
                "profileName": "KRAS G13D MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17527,
                    "pubMedId": 31416808,
                    "title": "Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31416808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19758,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (METROS), Xalkori (crizotinib) treatment resulted in progressive disease in a patient with pre-treated non-small cell lung cancer harboring MET amplification and BRAF D594G (PMID: 31416808; NCT02499614).",
            "molecularProfile": {
                "id": 34501,
                "profileName": "BRAF D594G MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17527,
                    "pubMedId": 31416808,
                    "title": "Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31416808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19759,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (METROS), Xalkori (crizotinib) treatment resulted in a partial response in a patient with pre-treated non-small cell lung cancer harboring MET amplification and a mutation in exon 14 of MET (PMID: 31416808; NCT02499614).",
            "molecularProfile": {
                "id": 34502,
                "profileName": "MET exon14 MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17527,
                    "pubMedId": 31416808,
                    "title": "Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non-Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31416808"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20348,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung cancer patient with MET amplification (18 copies) and MET D1010Y experienced stable disease when treated with Xalkori (crizotinib), but then progressed, and was found via tissue testing to have acquired additional copies of MET (47 copies) (PMID: 32034073).",
            "molecularProfile": {
                "id": 35138,
                "profileName": "MET D1010Y MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17807,
                    "pubMedId": 32034073,
                    "title": "Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32034073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20347,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung cancer patient with low copy number gain of MET and MET D1010Y demonstrated an initial response to treatment with Glesatinib (MGCD265), but then progressed, and was found via tissue testing to have acquired MET amplification (18 copies) (PMID: 32034073).",
            "molecularProfile": {
                "id": 35138,
                "profileName": "MET D1010Y MET amp"
            },
            "therapy": {
                "id": 809,
                "therapyName": "Glesatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17807,
                    "pubMedId": 32034073,
                    "title": "Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32034073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20349,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung cancer patient with MET amplification and MET D1010H demonstrated a partial response for 8.8 months when treated with Xalkori (crizotinib) (PMID: 32034073).",
            "molecularProfile": {
                "id": 35141,
                "profileName": "MET D1010H MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17807,
                    "pubMedId": 32034073,
                    "title": "Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32034073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20351,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung cancer patient with ERBB3 (HER3) amplification, MET amplification, and MET D1010N demonstrated a partial response for 13.3 months when treated with Xalkori (crizotinib) (PMID: 32034073).",
            "molecularProfile": {
                "id": 35147,
                "profileName": "ERBB3 amp MET D1010N MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17807,
                    "pubMedId": 32034073,
                    "title": "Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32034073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20354,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical study, a non-small cell lung cancer patient with MET D1010N, MET amplification, and ERBB3 (HER3) amplification initially responded to Xalkori (crizotinib), but then progressed, and was found via tissue testing and plasma testing to have acquired CCND1 amplification (PMID: 32034073).",
            "molecularProfile": {
                "id": 35150,
                "profileName": "CCND1 amp ERBB3 amp MET D1010N MET amp"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17807,
                    "pubMedId": 32034073,
                    "title": "Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14 mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32034073"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20385,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DFX117 treatment inhibited Pi3k/Akt and Met signaling, cell viability, and colony formation, and induced apoptosis and cell cycle arrest in a non-small lung carcinoma cell line harboring MET amplification and mutations in PIK3CA and EGFR in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 31060329).",
            "molecularProfile": {
                "id": 35157,
                "profileName": "EGFR mut MET amp PIK3CA mut"
            },
            "therapy": {
                "id": 9339,
                "therapyName": "DFX117",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17823,
                    "pubMedId": 31060329,
                    "title": "Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3K\u03b1 in Non-Small Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31060329"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20500,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial (TATTON), combination of Tagrisso (osimertinib) and Savolitinib (AZD6094) resulted in an objective response rate (ORR) of 67% (12/18, 12 partial response), a disease control rate (DCR) of 100% (18/18), and a median progression-free survival of 11.0 months in patients with EGFR-mutant, EGFR T790M-positive, MET-amplified non-small cell lung cancer after progression on first/second generation EGFR inhibitors (PMID: 32027846; NCT02143466).",
            "molecularProfile": {
                "id": 35213,
                "profileName": "EGFR T790M EGFR mut MET amp"
            },
            "therapy": {
                "id": 2224,
                "therapyName": "Osimertinib + Savolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17906,
                    "pubMedId": 32027846,
                    "title": "Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32027846"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20687,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, MET amplification was identified in a non-small cell lung cancer patient harboring EGFR S768I with primary resistance to icotinib (PMID: 31828849).",
            "molecularProfile": {
                "id": 35282,
                "profileName": "EGFR S768I MET amp"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17988,
                    "pubMedId": 31828849,
                    "title": "Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31828849"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20688,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, MET amplification was identified in a non-small cell lung cancer patient harboring an EGFR E709 mutation with primary resistance to icotinib (PMID: 31828849).",
            "molecularProfile": {
                "id": 35283,
                "profileName": "EGFR E709X MET amp"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17988,
                    "pubMedId": 31828849,
                    "title": "Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31828849"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20689,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, MET amplification was identified in a non-small cell lung cancer patient harboring EGFR S768I and an EGFR G719 mutation with primary resistance to icotinib (PMID: 31828849).",
            "molecularProfile": {
                "id": 35284,
                "profileName": "EGFR G719X EGFR S768I MET amp"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17988,
                    "pubMedId": 31828849,
                    "title": "Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31828849"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21046,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) in combination with Tykerb (lapatinib) treatment enhanced growth inhibition of an esophageal cancer cell line harboring ERBB2 (HER2) and MET amplifications and overexpressing ERBB2 (HER2) in culture (PMID: 30674502).",
            "molecularProfile": {
                "id": 35513,
                "profileName": "ERBB2 amp ERBB2 over exp MET amp"
            },
            "therapy": {
                "id": 9542,
                "therapyName": "Capmatinib + Lapatinib",
                "synonyms": null
            },
            "indication": {
                "id": 5041,
                "name": "esophageal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21101,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Capmatinib (INC280) treatment inhibited MET phosphorylation and induced tumor regression in a patient-derived xenograft (PDX) model of lung adenocarcinoma with a MET exon 14 skipping, overexpression, and an amplification with a moderate copy number gain of 5 (PMID: 30674502).",
            "molecularProfile": {
                "id": 35538,
                "profileName": "MET del exon14 MET amp MET over exp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3910,
                "name": "lung adenocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18298,
                    "pubMedId": 30674502,
                    "title": "Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30674502"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21139,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells with MET amplification demonstrated resistance to treatment with Capmatinib (INC280) and were subsequently found to have acquired amplification of PIK3CA in culture (PMID: 30309221).",
            "molecularProfile": {
                "id": 35557,
                "profileName": "MET amp PIK3CA amp"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 18419,
                    "pubMedId": 30309221,
                    "title": "Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30309221"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21135,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, non-small cell lung cancer cells with MET amplification and acquisition of PIK3CA amplification demonstrated sensitivity to the combination therapy of Piqray (alpelisib) and Capmatinib (INC280) in culture, resulting in decreased cell proliferation (PMID: 30309221).",
            "molecularProfile": {
                "id": 35557,
                "profileName": "MET amp PIK3CA amp"
            },
            "therapy": {
                "id": 9561,
                "therapyName": "Alpelisib + Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18419,
                    "pubMedId": 30309221,
                    "title": "Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30309221"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 1066,
            "profileName": "MET amp MET over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 1629,
            "profileName": "MET amp",
            "profileTreatmentApproaches": [
                {
                    "id": 14009,
                    "name": "HGF Antibody",
                    "profileName": "MET amp"
                },
                {
                    "id": 2550,
                    "name": "MET Inhibitor",
                    "profileName": "MET amp"
                },
                {
                    "id": 4232,
                    "name": "MET Antibody",
                    "profileName": "MET amp"
                }
            ]
        },
        {
            "id": 13346,
            "profileName": "SND1 - BRAF MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17215,
            "profileName": "ERBB2 amp MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17216,
            "profileName": "KRAS G12D MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 17304,
            "profileName": "EGFR amp MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 18241,
            "profileName": "EGFR exon 19 del EGFR T790M MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25627,
            "profileName": "EGFR exon 19 del MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25935,
            "profileName": "KRAS G12A MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 25979,
            "profileName": "KRAS G12V MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26181,
            "profileName": "BRAF V600E MDM2 amp MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26437,
            "profileName": "EGFR T790M MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26798,
            "profileName": "EGFR E746_A750del MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26799,
            "profileName": "EGFR L858R MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26887,
            "profileName": "EGFR exon 19 del MET D1228V MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26907,
            "profileName": "EGFR E746_A750del IGF1R pos MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26948,
            "profileName": "AXL over exp EGFR E746_E749del EGFR T790M MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28118,
            "profileName": "MET amp TP53 del",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28219,
            "profileName": "MET del exon14 MET G1163R MET D1228N MET Y1230H MET Y1230S MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28229,
            "profileName": "MET del exon14 MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28246,
            "profileName": "MET del exon14 MET G1163R MET L1195V MET D1228N MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28587,
            "profileName": "FGFR1 amp MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28588,
            "profileName": "EGFR mut MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28681,
            "profileName": "EGFR act mut MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 28961,
            "profileName": "ERBB2 pos MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29000,
            "profileName": "ERBB2 over exp MET R988C MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29001,
            "profileName": "ERBB2 over exp MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29158,
            "profileName": "KLC1 - ALK MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29713,
            "profileName": "ALK rearrange MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29877,
            "profileName": "BRAF V600E EGFR exon 19 del MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 29995,
            "profileName": "CD274 amp JAK2 amp MDM2 amp MET amp PDCD1LG2 amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30017,
            "profileName": "EGFR T790M EGFR L858R MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30018,
            "profileName": "EGFR T790M EGFR L858R MET D1228H MET D1228N MET Y1230H MET D1231Y MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 30020,
            "profileName": "EGFR T790M EGFR L858R MET D1231Y MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31176,
            "profileName": "ALK rearrange ALK I1171N MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31227,
            "profileName": "EGFR T790M EGFR act mut MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31573,
            "profileName": "BRAF V600E CDK6 amp EGFR amp KRAS Q61K MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31707,
            "profileName": "BRAF V600E KRAS amp MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31714,
            "profileName": "BRAF V600E MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31753,
            "profileName": "EGFR amp ERBB2 amp MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32092,
            "profileName": "MET D1228N MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32950,
            "profileName": "MET amp NTRK1 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32966,
            "profileName": "EGFR over exp MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33524,
            "profileName": "PLEKHA6 - NTRK1 MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 33935,
            "profileName": "PLEKHA6 - NTRK1 MET G1090A MET G1090S MET V1092I MET L1195V MET D1213H MET R1227K MET D1228H MET D1228N MET D1228Y MET Y1230C MET Y1230H MET Y1230N MET Y1230S MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34467,
            "profileName": "EGFR E746_S752del MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34468,
            "profileName": "EGFR S752_I759del MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34500,
            "profileName": "KRAS G13D MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34501,
            "profileName": "BRAF D594G MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34502,
            "profileName": "MET exon14 MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35138,
            "profileName": "MET D1010Y MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35141,
            "profileName": "MET D1010H MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35147,
            "profileName": "ERBB3 amp MET D1010N MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35150,
            "profileName": "CCND1 amp ERBB3 amp MET D1010N MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35157,
            "profileName": "EGFR mut MET amp PIK3CA mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35213,
            "profileName": "EGFR T790M EGFR mut MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35282,
            "profileName": "EGFR S768I MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35283,
            "profileName": "EGFR E709X MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35284,
            "profileName": "EGFR G719X EGFR S768I MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35513,
            "profileName": "ERBB2 amp ERBB2 over exp MET amp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35538,
            "profileName": "MET del exon14 MET amp MET over exp",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35557,
            "profileName": "MET amp PIK3CA amp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}